BRCA1 and ovarian cancer: Despite historical classification of ovarian cancer as poorly immunogenic, accumulating data show that TILs expressing PD‐1 correlate with overall survival and response to ICIs, particularly in BRCA1/2-mutant HGSC tumors with high PD‐L1 expression [11, 43–48].